DelveInsight's Exosome Therapies Market Insights report includes a comprehensive understanding of emerging exosome therapies, ...

Today, NurExone Biologic, headquartered in Haifa, Israel, is at the forefront of developing exosomes into next-generation nanocarriers for drug delivery. Drawing on deep expertise in exosome ...

A multi-institutional team of biochemical engineers has developed an exosome-based delivery system that can carry beneficial ...

The exosome diagnostic and therapeutic market is projected to grow at a CAGR of 9.1% from 2024 to 2034. Market valuation will increase from USD 88.56 million in 2024 to USD 211.6 million by 2034.

Dr. Rudnicki and his team discovered the exosome-targeting postal code or zip code within a protein called Wnt7a, which plays a critical role in development, growth, regeneration and cancer.

Exosomes have emerged as one of the most recent promising platforms for drug delivery and therapeutics for a wide range of diseases. Their distinctive properties such as innate stability, low ...

NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has ...

Researchers turn to cell culture conditioned medium (CCM) as a main source of exosomes for disease biomarker studies and drug delivery vehicles. Download this white paper from Thermo Fisher Scientific ...

Exosomes are a small, specific type of extracellular vesicle (EV), a kind of membrane-enclosed package that can move between cells. What separates them from other EVs is that they can carry a ...

ST. PETERSBURG, Fla., Jan. 6, 2025 /PRNewswire/ -- Marijuana, Inc. (OTCPINK: MAJI), dba Exousia Pro, Inc., has acquired 100% of Exousia AI in a cash and stock transaction from Ludwig Enterprises, Inc.